The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 06, 2019

Filed:

Feb. 07, 2019
Applicant:

Puretech Health Llc, Boston, MA (US);

Inventors:

Eric Elenko, Boston, MA (US);

Philip E. Murray, III, Somerville, MA (US);

Andrew C. Miller, East Walpole, MA (US);

Assignee:

PureTech Health LLC, Boston, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/46 (2006.01); A61K 9/48 (2006.01); A61K 31/4439 (2006.01); A61K 31/138 (2006.01); A61K 31/222 (2006.01); A61K 31/4025 (2006.01); A61K 31/4178 (2006.01); A61K 31/438 (2006.01); A61K 31/44 (2006.01); A61K 31/4725 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/46 (2013.01); A61K 9/48 (2013.01); A61K 9/485 (2013.01); A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 9/4891 (2013.01); A61K 31/138 (2013.01); A61K 31/222 (2013.01); A61K 31/4025 (2013.01); A61K 31/4178 (2013.01); A61K 31/438 (2013.01); A61K 31/44 (2013.01); A61K 31/4439 (2013.01); A61K 31/4725 (2013.01); A61K 45/06 (2013.01);
Abstract

Provided herein is a method of treating a central nervous system disorder in a patient in need thereof, wherein the central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia. The method comprises orally administering an initial dose of between 75 mg and 300 mg xanomeline and an initial dose of between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. Provided that the patient tolerates said administration, an increased dose of trospium chloride and an increased dose of xanomeline are orally administering to the patient, wherein the increased dose of trospium chloride is greater than the initial dose of the trospium chloride, and wherein the increased dose of xanomeline is greater than the initial dose of the xanomeline.


Find Patent Forward Citations

Loading…